BioSpace News Archive

Propeller Health’s digital medicines allow Anthem Blue Cross and Blue Shield consumers to better manage COPD symptoms

Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the issuance of U.S. Patent No. 10,040,769 covering the use of ricolinostat (ACY-1215) for the treatment of diabetic peripheral neuropathy (DPN).

Evecxia, Inc. today announced that its Board of Directors has appointed John Kaiser as Chief Executive Officer (CEO) and interim Chairman of the Board. Mr. Kaiser has been working with the company’s management team and Board since March 2018.

J-Meds, Inc. and Kalos Health Services, LLC announced today that the companies have executed a definitive partnership agreement.

Chairman of the Board of Directors, for the purchase of 3,225,807 shares of common stock priced at $1.55 per share, the last reported sale price of the common stock on the effective date.

Hesperos, Inc. has announced that it is among the first round of finalists for the 2018 Florida Companies to Watch honor, recently announced by GrowFL.

New research suggests that shifts in the bacteria within a child’s mouth could provide objective biomarkers for identifying autism spectrum disorder.

Pharmaceutical marketplace pioneer posts three-year revenue growth of 15,268%

The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine.

This approach was developed in collaboration with Renier J. Brentjens, M.D., Ph.D., Director of the Cellular Therapeutics Center at Memorial Sloan Kettering Cancer Center